We got some interesting biotech news and I thought there would be only one to talk about but we have three I want to touch on so I will save.
Nothing really to move the sector to start the week, so it looks like we sell off with the rest of the market. This price action does not change my.
The sector is certainly heating up and we still seem to be at the point where good news is rewarded and bad news is creating isolated damage. Not only do.
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.
A little but more news today and there are actually some interesting implications. Yesterday was actually not great in terms of trading given the weakening towards the end of the.
Another slow news start to the week. Without anything positive or negative to drive trading, I suspect we generally move with the market with perhaps some modest outperformance. The trend.
The rollercoaster ride continues but generally the sector has been an outperformer and even if there are occasional setbacks I expect that to continue. I take it as a positive.
I was a little late heading into the office this morning and had not been following the news and so I was a little surprised to see the market down.
An interesting start to the week. Stocks are starting off stronger than most expected (including me) with the sector slightly outperforming. We have some news to talk about but not.
Not a good day today (seems like rising rates freak out). I may not have been paying very close attention to the market but this seems like a drop on.
A modest start to the week for the sector but let us wait to see more of the week as more traders get back from vacation before claiming victory or.
More of the same in terms of the trading for the sector. We remain hostage of sentiment and low volume. Hopefully the pace of both news and volume will pick.
Not much to talk about today aside from continued underperformance of the sector. I think it is safe to say that the free fall is likely over (at least the.
Bellicum is a small biotech developing drugs in the hot field of adoptive cell therapeutics. Their lead candidate is a personalized T-cell product for use after stem cell transplants to prevent early.
Sector is doing well in essentially a flat market, although volumes generally remain low. It is the summer doldrums so the sector is not unique for low volumes. We have.
The sector is doing well on the consummation of the long courtship of MDVN. I will be back with my commentary this week but am still not quite back to.
We now seem to be stuck in a small rut with the near term trend being slightly negative and nothing really to break it. Perhaps value investors step in at.
We certainly have seen some recent under-performance by the sector but given recent strength and run of bad news (trial failures, secondaries, and so on) this is not stunning. So.
The sector seems to be struggling a little but it would not be stunning to see some underperformance and consolidation after the recent run. We continue to get earnings headlines.
I was not going to write today but snuck into office with my kids in tow for a quick note on BMY. 1. This was a major surprise and critically.